102 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…
If successful, this study could highlight a novel therapeutic benefit of semaglutide beyond its established roles in glycemic control and weight management. Identifying an effective pharmacological intervention for di…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
This case report is significant as it contributes to the emerging understanding of tirzepatide's potential adverse effects, specifically hepatotoxicity. The finding highlights the importance for clinicians to consider…
If BGM0504 demonstrates comparable or superior efficacy and safety to Tirzepatide, it could represent a significant advancement in the treatment landscape for obesity. A new therapeutic option would provide clinicians…
This Randomized Control Trial is highly significant as it explores a novel strategy to enhance the effectiveness of bariatric surgery, potentially offering a more robust solution for severe obesity. If successful, com…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…